Skip to content

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

PRESS RELEASES

Choose Year
Search Press Releases

Found 214 Results

March 1, 2022

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

February 28, 2022

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

November 8, 2021

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

November 3, 2021

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

November 1, 2021

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

October 11, 2021

Minerva Neurosciences Announces Promotion of Geoff Race to President

September 30, 2021

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

September 8, 2021

Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development

August 2, 2021

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

July 26, 2021

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

«...3 456 7...»

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803

Company

About Us
Leadership
Board of Directors
Contact

Science

Our Approach
Pipeline
Publications
Clinical Trials

Investors

Investors Overview
News
Events
SEC Filings
Stock Information
Corporate Governance
FAQs

© 2026 Minerva Neurosciences, Inc.

Privacy Policy
Terms of Use
Accessibility Statement
Cookie Policy

Scroll to Top